title: Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study.
abstract: OBJECTIVE
  Imatinib mesylate, a tyrosine kinase inhibitor, is presently the drug of choice for chronic myeloid leukemia (CML). During therapy, a few patients may develop hematological and non-hematological adverse effects.
  
  
  METHODS
  The aim of this study was to evaluate the safety of imatinib therapy in patients with CML. Between December 2007 and October 2009 two hundred patients with CML in chronic phase were included in the study. Written informed consent was obtained from all patients prior to the start of the study. Imatinib was started at 400 mg orally daily. Patients were monitored carefully for any adverse effects. Complete blood count, liver, and renal function tests were done once in 2 weeks during the first month and on a monthly basis during follow-up. Toxicities that encountered were graded as per the National Cancer Institute common toxicity criteria version 2. Both hematologic and non-hematologic toxicities were managed with short interruptions of treatment and supportive measures, but the daily dose of imatinib was not reduced below 300 mg/day.
  
  
  RESULTS
  Two hundred CML patients in chronic phase were included in this study; the male:female ratio was 0.7:1 with mean age 39.06±13.21 years (ranged from 15-81 years). The study showed that the commonest hematological side effects were grade 2 anemia (12.5%) followed by leukopenia (8%) and thrombocytopenia (4%), while the most common non-hematological adverse effects were superficial edema and weight gain (51.5%), followed by musculoskeletal pain (35.5%), then gastro-intestinal symptoms (vomiting, diarrhea) (19%). Fluid retention was the commonest side effect, which responded to low-dose diuretics. The drug was safe and well tolerated. There were no deaths due to toxicity.
  
  
  CONCLUSIONS
  Imatinib mesylate a well-tolerated drug, and all undesirable effects could be ameliorated easily. The most common hematological and non-hematological side effects were anemia and fluid retention, respectively Conflict of interest:None declared.
authors.affiliation: Baghdad Teaching Hospital, Clinical Hematology Department, Baghdad, Iraq.
authors.forename: Bassam Francis
authors.initials: BF
authors.lastname: Matti
authors.affiliation: Baghdad Teaching Hospital, Clinical Hematology Department, Baghdad, Iraq.
authors.forename: Alaa Fadhil
authors.initials: AF
authors.lastname: Alwan
authors.affiliation: National Center of Hematology, Clinical Hematology Department, Baghdad, Iraq.
authors.forename: Alaa Fadhil
authors.initials: AF
authors.lastname: Alwan
keywords: Chronic myeloid leukemia; Imatinib; Safety